AKBA Company Profile and Key Details

Q: Who are the executives of AKBA?

Ms. Meredith BowmanSenior Vice President of PeopleMs. Carolyn RucciSenior Vice President of Legal & Gen. CounselMercedes CarrascoDirector of Corporation CommunicationsMs. Violetta CotreauSenior Vice President, Chief Accounting Officer & Principal Accounting OfficerDr. Thierry Bilbault Ph.D.Senior Vice President of Manufacturing & Pharmaceutical Devel.Ms. Kimberly GarkoSenior Vice President of QualityMr. David A. SpellmanPrincipal Accounting Officer, Senior Vice President, Chief Financial Officer & TreasurerMs. Nicole R. HadasSenior Vice President, Chief Legal Officer & Sec.Mr. John P. Butler MBAChief Executive Officer, Pres & DirectorMs. Nicole R. Hadas J.D.Senior Vice President, Chief Legal Officer & Sec.Dr. Steven Keith BurkeSenior Vice President of R&D and Chief Medical OfficerMs. Ellen E. Snow CPA, CGMASenior Vice President, Chief Financial Officer, Treasurer & Principal Accounting OfficerTracey VetterickVice President of Portfolio Strategy & Corporation Admin.Mr. Michel DahanSenior Vice President & Chief Operating Officer

NASDAQ : AKBA

Akebia Therapeutics

$0.90

-0.0228-2.48%

Open: 4:00 PM

62.25

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Akebia Therapeutics, Inc. (AKBA) stock declined over -2.48%, trading at $0.90 on NASDAQ, down from the previous close of $0.92. The stock opened at $0.92, fluctuating between $0.89 and $0.93 in the recent session.

Stock Snapshot

0.919

Prev. Close

240.41M

Market Cap

0.893

Day Low

-9.14

P/E Ratio

-0.09803

EPS (TTM)

-0.12

Cash Flow per Share

0.92

Open

268.26M

Number of Shares

0.9268

Day High

97.98%

Free Float in %

-0.16

Book Value

4.37M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 25, 2026	0.92	0.93	0.89	0.90	4.37M
Sep 24, 2026	0.92	0.95	0.91	0.92	3.73M
Sep 23, 2026	0.99	0.99	0.93	0.93	5.38M
Sep 21, 2026	0.93	0.95	0.92	0.94	11.08M
Sep 18, 2026	0.89	0.93	0.88	0.92	7.37M
Sep 17, 2026	0.93	0.94	0.87	0.90	8.7M
Sep 16, 2026	0.91	0.94	0.90	0.92	7.5M
Sep 15, 2026	0.96	0.98	0.90	0.90	5.75M
Sep 14, 2026	0.95	1.02	0.90	0.96	8.83M
Sep 11, 2026	0.97	0.98	0.95	0.95	6.14M
Sep 10, 2026	0.95	0.97	0.93	0.95	4.92M
Sep 09, 2026	1.03	1.05	0.95	0.95	4.87M
Sep 08, 2026	0.96	1.03	0.95	1.03	3.06M
Sep 04, 2026	0.99	1.00	0.95	0.97	8.35M
Sep 03, 2026	1.00	1.00	0.96	0.98	7.46M
Sep 02, 2026	0.95	1.01	0.95	0.98	12.85M
Sep 01, 2026	0.91	0.95	0.91	0.94	12.45M
Aug 31, 2026	0.88	0.93	0.86	0.92	15.18M
Aug 28, 2026	0.94	0.94	0.87	0.88	10.17M
Aug 27, 2026	0.91	0.96	0.91	0.94	13.29M

Contact Details

Cambridge, MA 02142

United States

https://www.akebia.com 617 871 2098

About Company

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Stock Peers

ARGX

-2.73-0.28%

argenx SE$959.49 REGN

-7.98-1.00%

Regeneron Pharmaceuticals, Inc.$788.04 VRTX

3.81+0.73%

Vertex Pharmaceuticals Incorporated$526.19 MDGL

3.35+0.65%

Madrigal Pharmaceuticals, Inc.$516.56 UTHR

3.24+0.69%

United Therapeutics Corporation$475.45 ONC

0.88+0.24%

BeOne Medicines AG$360.85 KRYS

0.86+0.25%

Krystal Biotech, Inc.$345.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.48+0.83%

Ligand Pharmaceuticals Incorporated$301.52 PRAX

-1.01-0.36%

Praxis Precision Medicines, Inc.$280.78

Company Overview

Akebia Therapeutics, Inc. (NASDAQ:AKBA) closed at $0.90 USD, losing -$0.02 (-2.48%) from the previous close of $0.92. The stock is currently mid-range between its 52-week high and low $0.81 and $3.20. With a market capitalization of about $240.41 million, Akebia Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.23). Key stats such as the average daily volume over the past year has been around 6.03 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Akebia Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Butler, the company employs approximately 194 people and listed since March 20, 2014. Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases.

Technical Performance

AKBA has shown weak momentum, losing -4.29% over the past week and -54.27% over the past quarter, though year-to-date performance is down -16.77%. Short-term trend indicators are bullishly aligned (SMA20 -0.9%, SMA50 -8.5%, SMA200 -48.31%). The stock’s 14-day RSI is 48.07 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -67.64% below its high and over 15.79% above its low. Average 10-day trading volume of 6.77 million shares is slightly above the 3-month average of 6.03 million, indicating heightened recent market interest.

Valuation Metrics

Akebia Therapeutics, Inc. trades at a P/E ratio of -8.3, slightly below the S&P 500 average, with a price-to-sales ratio of 1.1 and a price-to-book ratio of 9.66 trading at moderately above to book value. The P/FCF stands at 5.98, also above market averages.

Dividend & Fair Value

Akebia Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.57. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Akebia Therapeutics, Inc. generated EPS of -$0.08 over the past year. Five-year average earnings growth is 32.58%. Wall Street analysts project EPS growth of 55.04% annually over the next five years. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at -$0.04. Next year's EPS is expected at $9.71. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $4.00. The high target offers 566.67% upside. The low target suggests 344.44% downside. The mean target is $5.15. This offers 472.22% upside. Akebia Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by -52.38%. The prior quarter beat by 200.0%. Over the last six quarters, Apple has recorded several small beats. These include -200.0% in May 08, 2025.

Shareholding & Insider Activity

Akebia Therapeutics, Inc. has 277.11 million shares outstanding. The public float is 270.60 million shares, elevated short interest at 8.42% of float. This equals 23.00 million shares. The short ratio is 2.95 days. Institutional investors hold 43.89% of the float. Insiders own 4.06%. Butler John P. holds 3.37 million shares, Satter Muneer A has 3.04 million shares and Burke Steven Keith has 948.43 thousand shares. Over the past six months, insider transactions show net selling. They sold 56.02 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Akebia Therapeutics generated $194.62M in revenue, or $1.04 per share. Gross margin was 61.09%, operating margin -23.67%, and net profit margin -26.68%. Returns are negative, with ROA at -21.48% and ROE at 169.78%.
On valuation metrics, Akebia Therapeutics trades at a P/E of -8.30, P/S of 1.10 and P/B of 9.66. The current ratio is 1.43 and quick ratio is 1.35. Operationally, the company’s inventory turnover is 3.45 and cash conversion cycle is 118.35 days. Debt-to-equity is 2.16, supported by a cash flow-to-debt ratio of 0.77.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Akebia Therapeutics posted revenue of $194.62M, down slightly from $292.60M in the prior quarter. Gross profit was $118.89M (margin 61.09%). Operating income was - $46.08M (margin -23.7%). Net income was- $51.93M (EPS - $0.28).
The company ended the quarter with $42.93M in cash and short-term investments, a total debt of $104.18M, and net debt of $61.26M. Total assets were $241.70M, with equity of - $30.58M. Financials further reflected weakness, with operating cash flow of - $23.38M, free cash flow of - $23.38M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Akebia Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.42%, with price expected at $0.90 by October 09, 2026, within a range of $0.86 to $0.94 3-Month Outlook: Projected fall of -29.7%, reaching $0.63 by December 24, 2026, with a range of $0.55 to $0.70. 1-Year Outlook: Projected gain of 28.32%, with price at $1.15 by September 24, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares are down -16.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Akebia Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.28, suggesting 823.9% upside. Our AI forecast model points to short-term strength (0.42% over two weeks), a medium-term fall (-29.7% over three months), and a longer-term gain (28.32% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Akebia Therapeutics, Inc. (AKBA) stock price?

Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock price is $0.90 in the last trading session. During the trading session, AKBA stock reached the peak price of $0.93 while $0.89 was the lowest point it dropped to. The percentage change in AKBA stock occurred in the recent session was -2.48% while the dollar amount for the price change in AKBA stock was - $0.02.

AKBA's industry and sector of operation?

The NASDAQ listed AKBA is part of Biotechnology industry that operates in the broader Healthcare sector. Akebia Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AKBA?

Ms. Meredith Bowman
Senior Vice President of People
Ms. Carolyn Rucci
Senior Vice President of Legal & Gen. Counsel
Mercedes Carrasco
Director of Corporation Communications
Ms. Violetta Cotreau
Senior Vice President, Chief Accounting Officer & Principal Accounting Officer
Dr. Thierry Bilbault Ph.D.
Senior Vice President of Manufacturing & Pharmaceutical Devel.
Ms. Kimberly Garko
Senior Vice President of Quality
Mr. David A. Spellman
Principal Accounting Officer, Senior Vice President, Chief Financial Officer & Treasurer
Ms. Nicole R. Hadas
Senior Vice President, Chief Legal Officer & Sec.
Mr. John P. Butler MBA
Chief Executive Officer, Pres & Director
Ms. Nicole R. Hadas J.D.
Senior Vice President, Chief Legal Officer & Sec.
Dr. Steven Keith Burke
Senior Vice President of R&D and Chief Medical Officer
Ms. Ellen E. Snow CPA, CGMA
Senior Vice President, Chief Financial Officer, Treasurer & Principal Accounting Officer
Tracey Vetterick
Vice President of Portfolio Strategy & Corporation Admin.
Mr. Michel Dahan
Senior Vice President & Chief Operating Officer

How AKBA did perform over past 52-week?

AKBA's closing price is 10.1% higher than its 52-week low of $0.81 where as its distance from 52-week high of $3.20 is -71.99%.

How many employees does AKBA have?

Number of AKBA employees currently stands at 194.

Link for AKBA official website?

Official Website of AKBA is: https://www.akebia.com

How do I contact AKBA?

AKBA could be contacted at phone 617 871 2098 and can also be accessed through its website. AKBA operates from 245 First Street, Cambridge, MA 02142, United States.

How many shares of AKBA are traded daily?

AKBA stock volume for the day was 4.37M shares. The average number of AKBA shares traded daily for last 3 months was 6.03M.

What is the market cap of AKBA currently?

The market value of AKBA currently stands at $240.41M with its latest stock price at $0.90 and 268.26M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	194
Beta	0.23
Sales or Revenue	$194.62M
5Y Sales Change%	-0.416%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AKBA Company Profile and Key Details

Akebia Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook